You can buy or sell TTPH and other stocks, options, ETFs, and crypto commission-free!
Tetraphase Pharmaceuticals, Inc. Common Stock, also called Tetraphase Pharmaceuticals, is engaged in the development and production of novel antibiotics for serious and life-threatening bacterial infections. Read More It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.
52 Week High
52 Week Low
Seeking AlphaMay 8
Tetraphase Pharmaceuticals' (TTPH) CEO Guy Macdonald on Q1 2019 Results - Earnings Call Transcript
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Jennifer Viera – Executive Director-Corporate Communications and Investor Relations Guy Macdonald – President and Chief Executive Officer Larry Edwards – Chief Operating Officer Larry Tsai – Chief Medical Officer Chris Watt – Senior Vice President-Finance Conference Call Participants Ted Tenthoff – Piper Jaffray Ellen Sands – Stifel Fang-Ke Huang – SunTrust Operator Good af...
Yahoo FinanceMay 2
Tetraphase Pharmaceuticals to Present Data at the 22nd Annual MAD-ID Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced five data presentations at the 22nd Annual MAD-ID (Making a Difference in Infectious Diseases) Meeting, taking place May 8-11, 2019 in Orlando, Fla. Presentations will include data on XERAVATM (eravacycline), a novel, fully-synthetic fluorocycline, approved by the U.S. Food and...
-$0.39 per share
-$0.36 per share